We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

CELLAVISION AB

CellaVision AB provides digital solutions for medical microscopy in the field of hematology, with its product portfol... read more Featured Products: More products

Download Mobile App




Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions

By LabMedica International staff writers
Posted on 07 Feb 2024
Print article
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)

Sysmex Corporation (Kobe, Japan) has entered into a strategic alliance agreement with CellaVision (Lund, Sweden) to advance hematology solutions. This collaboration aims to expand Sysmex's product range, including the development of cutting-edge cell morphology analyzers. Together, Sysmex and CellaVision will strive to improve the efficiency and standardization of testing workflows in hematology, enhance the accuracy of cell morphology classification, and provide valuable support in diagnostic processes.

The partnership between Sysmex and CellaVision has spanned 20 years, focusing on hematology, which involves the analysis of blood cells such as red and white blood cells in terms of their count, types, and sizes. This collaboration began in 2001 when Sysmex entered a sales alliance for CellaVision’s cell morphology analyzers. In 2013, Sysmex introduced the DI-60 Automated Digital Cell Morphology Analyzer, a product of its collaboration with CellaVision. This system, when integrated with Sysmex’s hematology analyzers, automates up to the cell morphology analysis stage, significantly streamlining and standardizing testing workflows in clinical laboratories worldwide.

The renewed partnership between the two companies aims to enhance their product offerings, particularly in next-generation cell morphology analyzers. They have agreed to extend their collaborative efforts to advance hematology solutions and maintain their agreement until 2038. Leveraging a stable, long-term collaborative framework, Sysmex plans to utilize its expertise in optimizing testing workflows in hematology, while CellaVision will contribute its advanced digital imaging and analysis technologies. These joint efforts are intended to further improve efficiency and standardization in testing workflows and increase clinical value by providing more precise cell morphology classification to aid in diagnoses.

“We are pleased to expand our alliance with CellaVision since 2013,” said Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation. “This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology.”

"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey,” said Simon Østergaard, President & CEO, CellaVision AB. “We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex.”

Related Links:
Sysmex Corporation
CellaVision 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.